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Abstract
BACKGROUND: Androgen receptor (AR) has emerged as a significant prognostic marker in early breast cancer
(BCa). Association of AR with cancer stem cell (CSC) markers in BCa is unknown. Aim of the present study was to
evaluate the immunohistochemical expression of AR, CD44, CD24 and ALDH1 in a cohort of Pakistani patients
diagnosed with invasive BCa and to correlate the expression with 5- year disease free survival. PATIENTS AND
METHODS: We evaluated immunohistochemical expression AR, CD44, CD24 and ALDH1 in formalin fixed paraffin
embedded archival blocks of 166 cases of primary invasive BCa (stage I-III) and correlated the expression with
clinicopathological variables and outcome using univariable and multivariable analysis. Survival data was computed by
Kaplan Meier curves. RESULTS: Expression of AR was observed in 62.7% tumors whereas CD44, CD24 and ALDH1
were expressed in 61.4%, 44% and 30.1% tumors, respectively. AR expression was significantly associated with T1T2 tumors, lower grade, estrogen and progesterone receptor expression (P b .05) and remained an independent
prognostic indicator in multivariable analysis (adjusted HR 0.33, 95% CI 0.13–0.81; P = .016). Significant association
was observed between concordant expression of AR and CD24 (P = .001) with a favorable impact on survival (P = .007)
whereas expression of CSC phenotypes (CD44 +, CD44 +/CD24 − and ALDH1 +) did not correlate with adverse
outcome (P N .05). However, AR expression retained the association with better prognosis even in patients whose
tumors exhibited a CSC phenotype. CONCLUSIONS: Expression of AR and CD24 in stage I-III invasive BCa correlates
with favorable clinicopathological features and delineates a subgroup of patients with better disease-free survival.
Translational Oncology (2018) 11, 920–929

Introduction
Androgen receptor (AR) is a ligand dependent transcription factor
variably expressed in 60–77% of early invasive breast cancers (BCa)
[1–4]. Expression of AR in BCa is associated with molecular subtypes
with highest expression observed in ER + tumors (78.4%) where AR

positivity has emerged as an independent prognostic marker
associated with favorable clinicopathological features, predictor of
response to chemotherapeutic and endocrine agents and better
survival [2,5–9]. These findings are in concordance with in vitro
studies demonstrating that AR signaling exerts an anti-estrogenic
effect by inhibiting ER mediated transcription of genes in luminal
BCa cell lines [10]. However, the interplay between AR and ER is
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complex as it is also influenced by levels of AR and ER in the tumor,
whereby AR to ER ratio of N2 selects for a subtype of ER +/AR +
tumors with an adverse outcome [11,12].
Androgen receptor expression is also observed in 12–40% of triple
negative breast cancers (TNBC) [13]. Considering the paucity of
targeted treatments, AR has evolved as a promising therapeutic target
in at least a subset of TNBC. This is well supported by in vitro studies
where targeting AR with anti-androgens yielded anti-proliferative
effect in a panel of TNBC cell lines [14]. However, the clinical
significance of AR expression in predicting outcome of patients with
TNBC remains ambiguous [13,15–17].
There is consensus that cancers evolve from a cancer stem cells
(CSCs) also referred to as the tumor initiating cells (TICs) [18]. CSCs
in solid tumors were first identified in human BCa by Al-Hajj and
colleagues who demonstrated that as few as 100 cells with CD44 +/
CD24 −/low /Lin − phenotype, isolated from primary or metastatic sites
can establish tumors and when serially passaged, transplantable in
nude mice [19]. Ginestier and colleagues identified an ALDH1 +
population of cells in normal and malignant human breast
epithelium. They showed that high expressing ALDH1 + cells derived
from BCa could be grown in vivo and xenotransplanted in an animal
model [20]. The defining characteristics of CSC include self-renewal,
clonal tumor initiation with a repopulating potential, phenotypic
plasticity and metastasis.
In addition, in vivo and in vitro studies have shown that CSCs are
quiescent, therapy resistant cells within the primary tumor and
metastatic sites. Disease recurrences are hence attributed to arise from
failure to eradicate the CSC population [18,21]. However, the clinical
significance of CSC phenotypes (CD44 +/CD24 − and ALDH1 +) in
BCa requires further investigation [22–25].
In vivo and in vitro studies investigating the biological interaction
between AR and ALDH1 in BCa are lacking and only limited studies
have addressed the mechanisms underpinning the regulation of CSC
phenotypes (CD44 + /CD24 − ) by AR and AR signaling with
conflicting results [26–28].
In view of these equivocal findings, it is important to determine if
there is any association and prognostic relevance of AR in relation to
CSC phenotypes. Hence, the aim of our study was to evaluate the
immunohistochemical expression of AR, CD44, CD24 and ALDH1 in
a cohort of Pakistani patients diagnosed with stage I-III invasive BCa and
to correlate the expression with clinicopathological features and survival.
Patients and Methods

Study Design
Aga Khan University Hospital (AKUH), Karachi, is one of the
principal, not for profit teaching institutions in Pakistan. It is a
710-bed tertiary care center that receives referrals from across the
country. Retrospective cohort study was undertaken and included
adult female patients diagnosed with stage I-III invasive BCa from
2006–2010. Cases were identified from prospectively maintained
BCa registry and included patients who had completed their
management at AKUH. Total of 930 patients were registered in
the defined study period, from which 166 cases were selected on basis
of the following criteria; 1) availability of formalin fixed paraffin
embedded (FFPE) archival blocks, 2) representative tumor tissue on
hematoxylin and eosin stained sections, and 3) follow up clinical data.
Medical records were reviewed, and data was collected on
structured questionnaire for clinico-pathological characteristics
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including age, menopausal status, TNM staging, surgical interventions and systemic therapies administered. In addition, data for
histological details including tumor type, size, grade, ER/PR, and
HER-2/neu expression and FISH analysis for HER-2/neu gene
amplification was collected. Follow-up details and outcome comprising of loco-regional recurrences and death were recorded. Study
protocol was approved by ethical review committee of Aga Khan
University, Pakistan campus (2517-Pat-ERC-13). All patients had
consented for their data and tumor tissues to be used for research. The
study was planned incorporating the REMARK guidelines [29].

Immunohistochemical Expression
FFPE archival tissue blocks were retrieved from department of
Pathology and Laboratory Medicine, AKUH. Appropriate blocks
were selected by the pathologist, based upon representative tumor
morphology on hematoxylin and eosin stained sections. Serial
sections of 5um were cut onto poly-L-lysine coated glass slides
(Dako-K8020).
For CD44, CD24 and ALDH1, sections were de-waxed in an oven
(Memmert, UK) at 70°C for 40 minutes followed by
de-paraffinization and gradual hydration in graded alcohol. Details
of antibodies, appropriate controls, method of antigen retrieval,
dilutions, incubation time and detection method are enlisted in
online Supplementary Table S1.

Immunohistochemical Scoring
CD44 & CD24. Scoring for membranous and cytoplasmic
expression of CD44 and CD24, respectively, was performed
according to previously published criteria as follows: No expression
(0); 1–10% positive tumor cells (1); 11–50% positive tumor cells
(2); 51–75% positive tumor cells (3); 76–100% positive tumor cells
(4) [30].
ALDH1. ALDH1 scoring was performed as described previously
[31]. Briefly, percentage and intensity of cytoplasmic expression was
recorded. Staining intensity was scored as 0 (no expression), 1 (weak
expression), 2 (moderate expression) and 3 (strong expression).
Product of percentage and intensity generated a numerical score (S =
P x I). For statistical analysis, scores = 0 were considered as negative
and positive expression was considered for all cases with scores N0.

AR
Nuclear expression of AR was scored in accordance with previously
published Allred criterion [32]. Briefly, percentage of AR expressing
cells was visually estimated. Allred score was calculated by taking into
consideration the proportion (P) scored as 0–5 and intensity (I) scored
as 1–3. Proportion and intensity were then summed up to generate a
score from 0 through 8. Score of ≥3 was considered to be positive.

Acquisition of Images
The slides were imaged on virtual scanning microscope (VS-120:
Olympus) at 20X and the images were acquired through Olympus
OlyVIA software.

Statistical Analysis
Statistical analysis was performed using SPSS version 20 software.
Descriptive statistics were computed for continuous (mean ± SD) and
categorical variables. Duration of follow-up was recorded from date of
diagnosis until death or until the date of last hospital visit at the time
of data collection. Loco-regional relapses and deaths were expressed as
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frequencies. Association between expression of AR, CSC markers and
clinico-pathological features was assessed by chi-square test or Fisher
exact test, where appropriate and P-value of b0.05 was considered to
be significant. Univariate analysis was performed by using cox
proportional hazard model and results were reported as crude hazard
ratio. All variables found to have a P-value of b0.2 were considered
eligible for multivariable analysis and adjusted hazard ratio with 95%
confidence intervals were reported using multiple cox proportional
hazard model. Event was defined as death attributed to BCa.
5-year disease free survival (DFS) was measured from date of
diagnosis until death due to BCa. Survival curves were acquired by
using Kaplan Meir methodology and significance between different
categories was determined by log rank analysis.
Results

Patient and Tumor Characteristics
Clinico-pathological characteristics of patients are summarized in
Table 1. The median age at diagnosis was 54 years (range: 28–87
years). Majority of tumors were invasive ductal (90.4%) followed by

Table 1. Clinical and Histopathological Characteristics of the Patients (n = 166)
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invasive lobular (3%) and remaining (6.6%) tumors belonged to
mucinous, papillary, metaplastic and tubulo-lobular subtypes. More
than half of patients (56.6%) were diagnosed with stage II. Positive
expression of ER, PR was found in 60.2% and 52.4% of tumors
respectively whereas HER-2/neu over-expression or amplification was
present in 30% of primary tumors. Amongst 166 cases, 46.4% were
luminal A (ER + and/or PR +, HER-2/neu −), 13.9% were luminal B
(ER + and/or PR +, HER-2/neu +) and 16.3% tumors were HER-2/neu
subtype and 23.5% were TNBC (ER −, PR −, HER-2/neu −) subtype.
Mastectomy was performed in 72.2% patients while breast
conservation was performed in 25% of cases. Systemic therapy was
administered in adjuvant and neo-adjuvant setting in 60.8% and
21.1% of the patients, respectively. Systemic therapy comprised of
adriamycin and taxane based chemotherapy in neo-adjuvant and
adjuvant setting in all patients with the exception of three patients
who were administered CMF (cyclophosphamide, Methotrexate and
5-Flourouracil) in adjuvant setting. Endocrine therapy was recommended where hormonal receptors were expressed and radiation
therapy was recommended in accordance with NCCN® (National
Comprehensive Cancer Network) guidelines. Mean duration of
follow-up was 4.6 years (SD± 2.7 years) and 42 deaths, attributed to
BCa were recorded in the entire cohort.

Immunohistochemical Expression of AR, CD24, CD44 and ALDH1
Features

n = 166 (%)

Age (years)
b40
40–49
50–59
60–64
N65
Tumor Grade
I
II
III
Tumor Size (cm)
T1
T2
T3
T4
Axillary Lymph Node Status
N0
N1
N2
N3
TNM Stage
I
II
III
Estrogen Receptor Expression
Positive
Negative
Progesterone Receptor Expression
Positive
Negative
HER-2/neu Expression
Positive
Negative
Androgen Receptor Expression
Positive
Negative
CD44 Expression
Positive
Negative
CD24 Expression
Positive
Negative
ALDH1 Expression
Positive
Negative

Median: 54 (Range:28–87)
20 (12)
45 (27.1)
38 (22.9)
24 (14.5)
39 (23.5)
15 (9)
97 (58.4)
54 (32.5)
20
86
37
23

(12)
(51.8)
(22.3)
(13.9)

89
43
17
17

(53.6)
(25.9)
(10.2)
(10.2)

27 (16.3)
94 (56.6)
45 (27.1)
100(60.2)
66 (39.8)
87 (52.4)
79 (47.6)
50 (30.1)
116 (69.9)
104 (62.7)
62 (37.3)
102 (61.4)
64 (38.6)
73 (44)
93 (56)
50 (30.1)
116 (69.9)

Overall, immunohistochemical expression of AR, CD44, CD24
and ALDH1 was observed in 62.7%, 61.4%, 44%, and 30.1% of
tumors, respectively (Table 1). Immunostaining of CD24 and
ALDH1 was predominantly cytoplasmic; whereas AR expression was
localized to nucleus and CD44 was found to have membranous
expression. Representative photomicrographs for expression of AR,
CD44, CD24 and ALDH1 along with representative hematoxylin
and eosin stained sections are presented in Figure 1 (A-D).

Association of Stem Cell Markers with Clinicopathological
Features and Survival
CD44 expression. CD44 expressing tumors comprised of two
groups: a) Expression observed in 1–10% of cells (26.5%); b)
Expression observed in N10% of cells (35%). Expression of CD44
varied significantly amongst BCa subtypes (P = .018) with highest
expression in luminal A (40.2%) and lowest in luminal B (11.8%)
while 16.7% of Her2/neu + and 31.4% of TNBC tumors expressed
CD44. Furthermore, CD44 + tumors were significantly associated with
positive expression of ER (P = .006) and low and intermediate grade (P
= .021) tumors. However, no association was found with disease stage,
axillary nodal status, PR, AR and HER-2/neu expression or
amplification (P N .05). There was no significant difference in 5-year
DFS of patients stratified by CD44 expression (P = .367) (Figure 2A).
CD24 expression. Amongst CD24 + tumors, 24.1% of cases
exhibited expression in 1–10% of cells while N10% of positivity was
demonstrated in remaining tumors (19.9%). No significant difference was observed between tumors with and without CD24
expression with respect to stage, axillary node status, grade, BCa
subtypes, ER, PR and HER-2/neu expression (P= N 0.05). Significant
concordant association was observed between AR and CD24
expressing tumors (P = .001). Remarkably, an adverse 5-year DFS
was observed in patients with CD24 − phenotype as compared to
tumors with CD24 + phenotype (P = .042) (Figure 2B).
CD44 +/CD24 − phenotype vs CD44 −/CD24 + Phenotype Expression. Cases were categorized into four groups based on CD44 and
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Figure 1. (A-D): Representative photomicrographs for expression AR (A2), CD44 (B2), CD24 (C2) and ALDH1 (D2) in invasive BCa along
with corresponding hematoxylin and eosin stained sections (A1-D1).

CD24 expression patterns. Group I: CD44 +/CD24 − (n = 59 cases);
Group II: CD44 +/CD24 − (n = 43 cases); Group III: CD44 −/CD24 −
(n = 34); Group IV: CD44 −/CD24 +(n = 30). The groups did not
differ with respect to stage, axillary node status, histological grade, PR,
HER-2/neu expression and BCa subtypes (P N .05). However, ER
expression was more frequent in group II (P = .028). Similarly, AR
was expressed in 76.7% of group II tumors as compared to 45.8% of
group I tumors (p-value = 0.005). The 5-year DFS between the
groups did not attain statistical significance (P = .159) (Figure 2C).
ALDH1. We did not observe a significant association of
ALDH1 expression with stage, axillary node status and HER-2/neu
expression (P N .05). Of the cohort of tumors negative for ALDH1
expression (n = 116), we found that a significant number were Grade
I and II tumors (P = b0.002). A significant association of discordance

was observed between ALDH1 and ER (ALDH1 −/ER +: P = .005),
PR (ALDH1 −/PR +: P = .036) and AR (ALDH1 −/AR +: P = .010).
Five-year DFS did not differ significantly between ALDH1 + and
ALDH1 − tumors (P = .153) (Figure 2D).

Association of AR with clinico-pathological features and
outcome
AR expression was significantly associated with intermediate
histological grade, expression of ER, PR and CD24 (P b .001) and
lack of ALDH1 expression (P = .010). No significant difference
was observed between AR + or AR − tumors with respect to age at
diagnosis, tumor size, axillary lymph node status, stage, HER-2/neu
over-expression or amplification and CD44 expression (Table 2).
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Figure 2. A-F: Kaplan Meier curves for 5-year DFS for expression of: A) CD44; B) CD24; C) CD44/CD24 phenotypes; D) ALDH1; E)
AR; F) AR and ER.

Frequency of AR expression revealed significant variation across
the BCa subtypes (P = b0.001). Amongst 104 (62.7%) AR + tumors,
AR expression was most frequently observed in luminal A (53.8%)
and luminal B tumors (19.2%), followed by TNBC (15.3%) and
HER-2/neu + subtype (11.5%). Significantly better 5-year DFS was
observed in patients with AR + tumors as compared to patients with
AR − tumors (P = .002) (Figure 2E). The concordant expression of AR
and ER (AR +/ER +) associated with a significantly improved outcome

(P b .001) as compared to concordantly negative tumors (AR −/ER −)
(2F).
Univariate analysis revealed axillary nodal metastasis (crude HR
2.31, 95% CI 0.99–5.41; P = .046), stage III (crude HR 3.16, 95%
CI 0.90–11.13; P = .002) and neo-adjuvant chemotherapy (crude
HR 2.32, 95% CI 1.01–5.30; P = .040) to be associated with adverse
outcome. Expression of ER (crude HR 0.28, 95% CI 0.12–0.64; P = .001),
PR (crude HR 0.27, 95% CI 0.11–0.68; P = .003) and AR (crude HR
0.0.28, 95% CI 0.12–0.66; P = .002) predicted better outcome. Subsequent
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Table 2. Clinical and Histopathological Characteristics Stratified by AR Expression (n = 166)
Features
Age at Diagnosis
b40
40–49
50–59
60–64
≥ 65
Tumor Size
T1
T2
T3
T4
Axillary Nodal Status
N0
N1
N2
N3
Grade of Tumor
I
II
III
Stage of Disease
I
II
III
ER Expression
Positive
Negative
PR Expression
Positive
Negative
HER-2/neu Status
Positive
Negative
CD44 Expression
Positive
Negative
CD24 Expression
Positive
Negative
ALDH1 Expression
Positive
Negative
Triple Negative
Yes
No

AR Positive
n = 104 (62.7)

AR Negative
n = 62 (37.3)

13
23
23
15
30

(12.5)
(22.1)
(22.1)
(14.4)
(28.8)

7 (11.3)
22 (35.5)
15 (24.2)
9 (14.5)
9 (14.5)

0.193

16
49
21
18

(15.4)
(47.1)
(20.1)
(17.3)

4 (6.5)
37 (59.7)
16 (25.8)
5 (8)

0.082

54
28
10
12

(51.9)
(26.9)
(9.6)
(11.5)

35 (56.5)
15 (24.2)
7 (11.3)
5 (8)

0.844

13 (12.5)
71 (68.3)
20 (19.2)

2 (3.2)
26 (41.9)
34 (54.8)

b0.001*

20 (19.2)
55 (52.9)
29 (27.9)

7 (11.3)
39 (62.9)
16 (25.8)

0.324

76 (73.1)
28 (26.9)

24 (38.7)
38 (61.3)

b0.001*

66 (63.5)
38 (36.5)

21 (33.9)
41 (66.1)

b0.001*

32 (30.8)
72 (69.2)

18 (29)
44 (70.9)

0.813

60 (57.7)
44 (42.3)

42 (67.8)
20 (32.2)

0.198

56 (53.8)
48 (46.2)

17 (27.4)
45 (72.6)

0.001*

24 (23)
80 (76.9)

26 (41.9)
36 (58)

0.010*

13 (12.5)
91 (87.5)

20 (32.3)
42 (67.7)

0.002*
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Table 3. Cox Univariable and Multivariable Analysis of Clinical and Pathological Variables for
Mortality in Patients with Invasive BCa (n = 166)

P-value
Variables

multivariable analysis confirmed ER (adjusted HR 0.35, 95% CI
0.14–0.85; P = .021) and AR expression (adjusted HR 0.33, 95% CI
0.13–0.81; P = .016) to be independently associated with improved
outcome (Table 3).

Impact of AR Expression On Survival In Tumors with Stem
Cell Marker Expression
To investigate the prognostic relevance of AR in relation to CSC
markers, we performed sub-group analysis where tumors identified with
CSC phenotype were individually stratified for AR expression. We
found that concordant expression of AR with CD44, ALDH1 and
CD44 + /CD24 − phenotypes (CD44 + /AR + , ALDH1 + /AR + and
CD44 +/CD24 −/AR +, respectively) selected for a cohort of patients
with a significantly better outcome. CD44 +/AR + tumors had a mean
survival time of 4.9 ± 0.0.06 years as compared to CD44 +/AR − tumors
(3.9 ± 0.26 years) (P = .001). Similarly, ALDH1 +/AR + phenotype also
demonstrated a better outcome with a mean survival time of 4.85± 0.13
years as compared to mean survival time of 3.79± 0.36 years in tumors
with ALDH1 +/AR − phenotype (P = .012). Likewise, AR expression in
tumors with CD44 +/CD24 − cases was associated with significantly

Crude Hazard
Ratio (95% CI)

Age at Diagnosis
b40
1
40–49
0.81 (0.24–2.77)
50–59
0.90 (0.26–3.08)
60–64
0.46 (0.08–2.51)
N65
0.70 (0.18–2.82)
Tumor Grade
I
1
II
1.87 (0.24–14.28)
III
3.64 (0.47–28.19)
Axillary Lymph Nodes
Negative
1
Positive
2.31 (0.99–5.41)
Stage of Disease
I
1
II
0.80 (0.21–3.01)
III
3.16 (0.90–11.13)
Adjuvant Chemotherapy
No
1
Yes
0.46 (0.20–1.03)
Neo-adjuvant Chemotherapy
No
1
Yes
2.32 (1.01–5.30)
Endocrine Therapy
No
1
Yes
0.29 (0.12–0.68)
ER Expression
No
1
Yes
0.28 (0.12–0.64)
PR Expression
No
1
Yes
0.27 (0.11–0.68)
HER-2/neu
Negative
1
Positive
1.02 (0.42–2.47)
AR Expression
Negative
1
Positive
0.28 (0.12–0.66)
CD44 Expression
Negative
1
Positive
1.47 (0.63–3.45)
CD24 Expression
Negative
1
Positive
0.39 (0.16–0.99)
ALDH1 Expression
Negative
1
Positive
1.79 (0.79–4.04)

P-value

Adjusted hazard
Ratio (95% CI)

P-value

0.909

-

-

0.162

-

-

0.046

-

-

0.002

1
0.71 (0.18–2.67)
3.21 (0.92–11.29)

0.0028*

0.055

-

-

0.040

-

-

0.003

-

-

0.001

1
0.35 (0.14–0.85)

0.021*

0.003

-

-

0.959

-

-

0.002

1
0.33 (0.13–0.81)

0.016*

0.368

-

-

0.042

-

-

0.153

-

-

favorable outcome (P = .007) with mean survival time of 4.9 years±0.54
years as opposed to AR −/CD44 +/CD24 − cases with lower mean
survival time (3.79± 0.36 years) (Figure 3A-C).
Interestingly, concordant expression of AR and CD24 (CD24 +/
AR +) conferred a significant survival advantage (mean: 4.9 ± 0.05
years) as compared to tumors with AR −/CD24 − phenotype (mean:
4.02± 0.24 years) (P = .007) (Figure 3D). Expression of AR and
CD24 was also associated with a significant survival advantage in
TNBC (P = .021 and P = .022 respectively) as shown in Figure 3E-F.
Discussion
To the best of our knowledge, this is the first study to date, examining
the clinical significance of individual and combined expression of
putative CSC phenotypes (CD44 +, CD44 +/CD24 − and ALDH1 +)
together with AR on clinical samples of primary invasive BCa with its
implications on patient survival.
Salient findings of our study of stage I-III invasive BCa are:
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a) Lack of association CSC phenotypes (CD44 +, CD44 +/CD24 −
and ALDH1 +) with 5-year DFS;
b) Patients with tumors expressing CD24 showed a significantly
better 5-year DFS (P = .042);
c) Significantly improved 5-year DFS survival observed in patients
whose tumors expressed AR (P = .002);
d) Patients with tumors expressing concordant AR and CD24
showed a significantly better 5-year DFS (P = .007).
In 2003, Al-Hajj and colleagues were the first to identify a CSC
population in BCa with a CD44 +/CD24 −/Lin − phenotype [19].
Four years later in 2007, Ginestier and colleagues identified ALDH1 +
CSC population in samples of normal and malignant breast
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epithelium [20]. Subsequently, the existence and potential relevance
of CSCs with either CD44 +/CD24 − and ALDH1 + phenotypes were
validated in several in vitro and in vivo studies [33–35]. In our study
we did not observe a significant association of CSC phenotypes
(CD44 +/CD24 − and ALDH1 +) with 5-year DFS.
There are several potential explanations for these discrepant
findings including the following:
a) Influence of the tumor microenvironment: In vitro studies utilizing
BCa cell lines and the serial transplantation assays are devoid of
the tumor microenvironment (TME), whereas, the in vivo studies
on patient tumor samples have a preserved TME. The CSC niche

Figure 3. A-F: Kaplan Meier curves for 5-year DFS for: A) CD44 + cases stratified by AR expression (n = 102); B) ALDH1 and AR expression
(n = 166); C) AR and CD44 +/CD24 − phenotype (n = 59); D) CD24 and AR expression (n = 166); E & F) TNBC cases stratified by expression
of AR and CD24.
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comprises of extra cellular matrix, fibroblasts, endothelial cells,
perivascular cells and a myriad of signaling molecules including
growth factor and cytokines [18]. The CSC niche plays a pivotal
role in determining stem cell fate via cues from cell–cell
interaction and paracrine factors [21]. It is therefore not surprising
to observe discordant observations between in vitro and in vivo
studies on patient tumor samples.
b) CSCs exhibit phenotypic plasticity by their capacity to reversibly
interconvert between a differentiated and stem cell fate [36]. It is
therefore conceivable that a CSC with a CD44 + /CD24 −
phenotype transitioned to a differentiated cell exhibiting
CD24 + phenotype and further differentiating into a clone with
CD24 +/AR + phenotype, thus becoming a dominant clone within
the tumor likely associated with favorable outcome.
c) Dormancy is yet another factor which should be taken into
consideration in the evolution of tumor. It is perhaps conceivable
that over the course of a longer follow up, the dormant CD44 +/
CD24 −/low phenotype could transition from the state of
quiescence into a phenotype capable of metastasis and hence
poor outcome.
Hence the findings from our study coupled with those from the
other studies should be interpreted with caution as there are several
factors which influence these observations and conclusions.
With reference to expression of AR, our findings are in agreement
with several previous studies signifying the prognostic relevance of AR
as a powerful predictor of improved survival associated with small
tumors, low grade and ER/PR expression [3,5,37,38].
Our study has examined the immunohistochemical expression and
prognostic implication of AR and CSC markers which has not been
described before. The sub-group analysis has demonstrated a survival
benefit with concordant expression of CD44 and AR (CD44 +/AR +) as
compared to tumors with a discordant expression phenotype (CD44 +/
AR −). Concordant expression of AR with ALDH1 (ALDH1 +/AR +)
and CD44 +/CD24 − (CD44 +/CD24 −/AR +) sub-groups also displayed
a similar trend towards survival advantage. Only two studies have
reported expression of AR with ALDH1 however, in both these studies
no significant association was found between AR and ALDH1 [39,40].
The mechanisms of biological interaction of AR signaling with CSC
markers has been addressed in a few in vitro studies with inconsistent
results. Zhang et al. demonstrated that ligand activated AR in MCF-7
inhibited tumor initiation, self-renewal and invasive potential via
transcriptional up-regulation of Let 7a [12]. In contrast, Feng et al.
demonstrated that AR signaling in MCF-7 induced epithelial
mesenchymal transition (EMT) program with enhanced invasion,
migration, self-renewal and enrichment of CD44 + /CD24 − phenotype [27]. Barton et al. provided evidence demonstrating that AR
mRNA, protein and transcriptional activity increased under
anchorage independent conditions using TNBC cell lines and AR
inhibition by enzalutamide decreased CSC population [14].
Although these studies add to the understanding of AR and CSC
interaction, however, AR signaling pathways regulating CSC across
the various molecular subtypes of BCa require further insight.
CD24 is a glycosylphosphatidylinositol-linked cell adhesion
protein expressed in several malignancies including BCa [41]. We
found that its expression in tumors was associated with significantly
better survival (P = .042) that was enhanced when there was
concordant expression with AR (P = .007). Bensimon et al.
demonstrated that CD24 − cells had lower proliferation rates, lower
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levels of reactive oxygen species and decreased genomic stability
whereas CD24 + tumors showed the converse, concluding that the
loss of CD24 leads to radiation resistance [42,43]. Ju et al. showed
that forced expression of CD24 in MDA-MB231 resulted in
decreased proliferation, down-regulation of cRAF /MEK/MAPK
pathway and increased apoptosis through inhibition of NF- B
signaling pathway [44]. This contrasts with immunohistochemical
studies of Kristiansen et al. and Kwon et al. demonstrating CD24 as a
poor prognostic marker [41,45]. These conflicting data are probably
due to the differing experimental approaches, factors related to tissue
fixation, immunohistochemical cutoff points and genetic background
of patients, amongst others.
In TNBC tumors we found that AR and CD24 conferred a survival
advantage. Role of AR in these aggressive tumors requires further
elucidation as data on the potential role of AR in TNBC is equivocal. AR
expression in TNBC has been associated with older age, advanced disease,
lymph node metastasis, high Ki-67, lymphovascular invasion, and poor
survival [15,16,39]. Conversely, other studies have demonstrated that AR
expression in TNBC correlates with well-differentiated tumors with
decreased incidence of lymph node metastasis and better survival [46].
Likewise, CD24 expression has been associated with either adverse
outcome or has failed to show any association with survival in TNBC
[45]. Biological interaction between AR and CD24 has been
demonstrated in bladder cancer, where CD24 transcriptional activity
was enhanced via ligand activated AR through its interaction with
androgen response elements located upstream of CD24 promoter [47].
Significance of AR and CD24 in BCa requires further elucidation.
The limitations of our study include: a) Small sample size: In
Pakistan, as in most low/middle income countries, patients are either
lost to follow up or attend different institutions for treatment, which
makes it challenging to undertake long term survival studies on a large
cohort of patients; b) Undertaking single as opposed to double
immunostaining which may have identified the various co-expressing
population of cells with a higher precision.
Conclusions
In our study, amongst the analyzed biomarkers, only AR and CD24
significantly correlated with favorable clinicopathological features and
an improved survival whereas CSC markers such as CD44 +, CD44 +/
CD24 − and ALDH1 + were not effective prognostic indicators for
outcome prediction.
These findings are contributory to existing literature where AR has
emerged as an important prognostic marker in BCa with promising
therapeutic application. Studies on larger cohorts are warranted for
substantiation of our results. Moreover, routine assessment of AR in
BCa may provide valuable insight for disease prognostication and for
identification of low-risk patient population.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2018.05.002.
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